FM
GYRE icon

Fondren Management’s Gyre Therapeutics GYRE Stock Holding History

Fondren Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,333
Closed -$272K – 86
2019
Q4 		$272K Sell
5,333
-6,579
-55% -$276K 0.28% 75
2019
Q3 		$439K Buy
+11,912
New +$642K 0.37% 63

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Fondren Management's GYRE Position: Q1 2020 in Review

Fondren Management sold out of Gyre Therapeutics (GYRE) in Q1 2020, closing a stake of 5,333 shares — an estimated $272K sold.

Fondren Management first reported a position in GYRE in Q3 2019 and held it in 2 quarters. The position peaked at $439K in Q3 2019. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2020.

  • Fondren Management reported no remaining Gyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Fondren Management sold 5,333 Gyre Therapeutics shares in Q1 2020, an estimated $272K.
  • Fondren Management first reported a position in Gyre Therapeutics in Q3 2019 and held it in 2 quarters.
  • Fondren Management's Gyre Therapeutics position peaked at $439K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2020.

Based on Fondren Management's 13F filing for Q1 2020, filed 15 May 2020.